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Abstract
Background: Pathway analysis of a set of genes represents an important area in large-scale omic data analysis. However, the
application of traditional pathway enrichment methods to next-generation sequencing (NGS) data is prone to several
potential biases, including genomic/genetic factors (e.g., the particular disease and gene length) and environmental factors
(e.g., personal life-style and frequency and dosage of exposure to mutagens). Therefore, novel methods are urgently needed
for these new data types, especially for individual-specific genome data.
Methodology: In this study, we proposed a novel method for the pathway analysis of NGS mutation data by explicitly
taking into account the gene-wise mutation rate. We estimated the gene-wise mutation rate based on the individual-
specific background mutation rate along with the gene length. Taking the mutation rate as a weight for each gene, our
weighted resampling strategy builds the null distribution for each pathway while matching the gene length patterns. The
empirical P value obtained then provides an adjusted statistical evaluation.
Principal Findings/Conclusions: We demonstrated our weighted resampling method to a lung adenocarcinomas dataset
and a glioblastoma dataset, and compared it to other widely applied methods. By explicitly adjusting gene-length, the
weighted resampling method performs as well as the standard methods for significant pathways with strong evidence.
Importantly, our method could effectively reject many marginally significant pathways detected by standard methods,
including several long-gene-based, cancer-unrelated pathways. We further demonstrated that by reducing such biases,
pathway crosstalk for each individual and pathway co-mutation map across multiple individuals can be objectively explored
and evaluated. This method performs pathway analysis in a sample-centered fashion, and provides an alternative way for
accurate analysis of cancer-personalized genomes. It can be extended to other types of genomic data (genotyping and
methylation) that have similar bias problems.
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Introduction
In large-scale sequencing studies of cancer genomes, one of the
central challenges is to distinguish disease-causing ‘‘driver’’
mutations from ‘‘passenger’’ mutations, and allow the develop-
ment of targeted therapy and medication. While statistical
methods have been under active development to test mutation
events at the gene level, the combinatorial occurrence of many
genes shows distinguishable patterns. Some well-studied examples
include mutually exclusive mutations such as EGFR and KRAS in
lung cancer [1], and TP53 and MDM2 in glioblastoma. Most of
these mutations were frequently observed in certain focused
pathways, e.g., four genes from the EGFR-RAS-RAF signaling
pathway, EGFR, KRAS, HER2, and BRAF, behave in a mutual
exclusive fashion in lung cancer [1,2]. In addition, the most recent
findings of The Cancer Genome Atlas (TCGA) projects strongly
suggested the convergence of mutations at the pathway level (e.g.,
three key pathways in glioblastoma, [3]).These observations
promoted an emerging consensus that driver genes could be
analyzed at the pathway level and induce more straightforward
functional interpretation.
The rapid advance in next-generation sequencing (NGS)
technologies has made it possible to sequence individual genomes
in a timely and cost-efficient manner. For example, whole genome
sequencing can provide a full spectrum of the genetic mutations,
including single nucleotide variants (SNVs), short insertions/
deletions (indels), copy number variations (CNVs), and structure
variants. So far, many individual cancer genomes have been
successfully sequenced [4,5,6], and even more are expected in the
near future. These applications provide valuable sequencing data
for individual genomes and make it possible to conduct analysis in
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personalized diagnose and medication.
In this work, we aimed to perform a pathway-enrichment test of
a group of putative cancer genes detected in individual patients. In
contrast to most traditional data types, personalized sequencing
data is typically complicated by the following features: (1) the
mutated genes are related to one individual and likely differ across
multiple individuals; (2) the mutated genes occur at an individual-
specific background mutation rate, which could be subject to
personal life-style, the frequency and dosage of exposure to
mutagens, and the particular disease; and (3) the mutated genes
are attributed to gene length under the assumption that mutations
evenly occur across the whole genome. Due to these challenges,
methods that have been well-studied and widely applied in
standard gene set analyses are not directly applicable. For
example, a functional enrichment test is an important way to
explore the biological functions for a list of genes of interest.
Traditionally, the genes of interest are derived through studies of a
group of samples, e.g., differentially expressed (DE) genes derived
from case/control design, and standard statistical tests such as the
hypergeometric test or Fisher’s exact test can be performed to test
if a gene set (e.g., pathway or functional group) is significantly
enriched with DE genes. Notably, a common assumption
underlying these tests is that all the genes (corresponding to the
balls in an urn) have an equal chance of being selected. However,
when applied to NGS data, the mutation unit is genomic DNA,
e.g., SNVs or small insertions/deletions (indels), and they are
assumed to occur evenly across the genome. In contrast, the
analyzing unit of a pathway enrichment test is gene. A bias
frequently observed in the process of relating SNVs or indels to
genes is that long genes tend to harbor more mutations, as they
occupy larger parts of the genome, and thus, long genes tend to
have higher chance to be mutated. Therefore, the standard
hypergeometric test or Fisher’s exact test is no longer applicable to
such data types.
The long gene effect has been recognized in NGS mutation
data. In the recent work of Wendl et al. [7], to estimate the
probability of a pathway being enriched with mutated genes, a
brute force way of computing the exact P values was described,
and a convolution-based approximation strategy was proposed
aiming to reduce the computational burden. The gene length bias
has also been recognized in RNA sequencing data, in which long
transcripts tend to have more reads mapped to them. In the work
by Young et al. [8], the authors proposed to fit a probability
weighting function and quantitatively estimate the probability of a
transcript being selected as DE as a function of its transcript
length. The Gene Ontology (GO) enrichment test is then
performed based on the estimated probability for each tran-
script/gene. Notably, the gene length bias appears in many aspects
of pathway-related analysis, such as pathway crosstalk within each
sample and pathway co-mutation profile across multiple samples
[9]. Appropriate adjustment could warrant the accuracy of these
analyses.
In this study, we proposed a bias-reducing strategy for pathway
enrichment test by taking the background of gene-specific
mutation rates. This strategy, namely the weighted resampling
method, takes into account gene length to estimate the pathway P
values and has proved to be computationally efficient. Under the
weighted resampling framework, personalized pathway crosstalk
could subsequently be explored, revealing the complex interaction
at the pathway level. In addition, we showed that with effective
reduction of gene length bias, a more functionally relevant co-
mutated pathway map could be derived. The work we proposed
here will find wide applications in the near future as more
personalized sequencing data are expected to be available.
Materials and Methods
Datasets
Pathway collection. We collected all the pathways from
KEGG [10] using the R package ‘org.Hs.eg.db’ (version 2.5.0), in
which the KEGG pathways were downloaded as of March 15,
2011. A total of 229 pathways and 5891 genes were involved in
this version. To avoid pathways defined for too specific or too
Figure 1. The flowchart of the pathway enrichment pipeline. For a given sample, suppose there are a total of n genes in the genome, G={gi;
i=1,…, n}, and N of them are mutation genes (MutGenes). MutGenes are labeled as 1 while the others are labeled as 0. (a) Hypergeometric test. (b)
Regular resampling. (c) Weighted resampling. (d) The three analysis scenarios we performed.
doi:10.1371/journal.pone.0037595.g001
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at most 500 genes, resulting in 213 valid pathways for our
subsequent analysis.
Lung adenocarcinomas data. The lung cancer dataset was
initially reported in Ding et al. [11], in which a total of 188 lung
adenocarcinomas samples were sequenced for 623 genes. In
summary, 163 samples were observed to have mutations in at least
one gene, and 356 genes were observed to have mutation(s) in at
least one sample. To ensure the statistical power, we included only
those samples having at least 10 mutated genes (Figure S1). This
filtering rule resulted in 33 samples with 277 genes involved, and
they were subsequently used as our working dataset. The
background mutation rate was set as 2.7610
26 for these samples
as indicated in the original work [11].
Glioblastoma data. The glioblastoma data detected 223
genes with at least one non-silent somatic mutation in one or more
samples with experimental validation [3]. A total of 91 samples
were examined, including 72 untreated cases and 19 treated cases.
To ensure statistical power, we required that a sample would be
included for our follow up analysis if it has $5 mutated genes. We
selected this less stringent cutoff here compared to lung samples
due to sample-specific features. As shown in Figure S1, there
would be only a few samples remaining if we applied 10 in the
glioblastoma data. Thus, using 5 as the cutoff value, 18 samples
remained suitable for the following pathway analysis.
As identified in the original work [3], there are 7 hypermutated
glioblastoma samples with a high somatic mutation rate, all of
which belong to treated samples. These samples resulted in an
unequal background mutation rate for treated and untreated
samples. Accordingly, we set the mutation rate to be 3.7610
26 for
untreated samples and 6.4610
26 for treated samples (http://tcga-
data.nci.nih.gov/docs/publications/gbm_2008/TCGA_GBM_
Level4_Significant_Genes_by_Mutations_DataFreeze2.xls).
Weighted resampling based pathway enrichment test in
single sample
The underlying assumption of the standard hypergeometric test
in gene set enrichment analysis is that all the genes in the genome
have an equal chance to be selected. This assumption is no longer
valid when the analyzing unit is transferred from mutations to
genes, because longer genes tend to have more chances to harbor
mutations, assuming the mutations evenly occur across the
genome. Thus, the standard hypergeometric test is not applicable
in such cases. To this end, we proposed a weighted resampling
strategy to build the null distribution, and compared the observed
mutated genes in each pathway with the estimated null
distribution.
Let m be the background mutation rate for a cancer sample.
Previous studies have shown that m is on the order of 10
26/nt [12]
and varies greatly in different diseases [11,12]. Here, nt denotes
nucleotide. Let l be the gene length and li for the i
th gene, and
G={gi; i=1,…, n} be the set of all genes for a total of n genes in
the genome. Assuming a genomic locus (e.g., nucleotide position)
in the genome has two statuses, mutated or not, the probability of
the i
th gene, gi, not being mutated could be formulated as
exp(2m6li) according to the Bernoulli probability, where exp is the
exponential function. Accordingly, its mutation rate is
mi=12exp(2m6li). We noted that the estimation of the gene-wise
mutation rate could be more complex than simply replying on
gene length. Here, we specifically adjusted the gene length bias
[7], while a more detailed theorem could be found in literature
[12,13,14,15].
Suppose in an individual genome, a total of N genes were
detected as mutated among G={gi; i=1,…, n}, and we denote
them as ‘‘MutGene(s)’’, where MutGenes(G. We assign a label
for each gene to indicate its mutation status: yi~
1,mutated
0,not mutated

, i~1,:::,n (Figure 1). Given a pathway S with
k MutGenes, our aim is to provide a statistical test to examine
whether S is significantly enriched with MutGenes. To do so, we
can build a null distribution of the MutGenes by randomizing
gene labels (Figure 1). Normally, unweighted randomization
process assumes every gene has the same chance to be selected
as MutGenes. For example, for the n genes in G, a random
number is generated for each of them, i.e., frig, where ri[½0,1  and
i=1,…, n. Thus, by ordering genes according to their ri values,
gene symbols are randomized while MutGene label, yi, is fixed
(Figure 1b). Repeating this way of permuting gene labels for many
times (e.g., 10,000), the background distribution of MutGenes for
each pathway can be constructed and the significance of the
pathway can subsequently be estimated. This resamping based
method of estimating pathway enrichment is complementary to
the hypergeometric test, both of which build on the assumption
that all the genes have an equal chance to be selected.
In contrast, we proposed the weighted resampling strategy
which aims to build the null distribution by projecting each
distribution with the same pattern of gene length bias (Figure 1c).
Specifically, in each weighted resampling, frig is generated in the
Figure 2. Pathway enrichment test in the lung adenocarcino-
mas samples. Pathways are represented as rectangles and organized
by samples. For each sample, the sample ID is presented on the left and
the three rows on the right correspond to results from the weighted
resampling method (top row), the regular resampling method (middle
row), and hypergeometric test (bottom row), respectively. For each
method, the pathways were placed from left to right according to their
P values with lower P values on the left, and, when multiple pathways
have the same P values, they were ordered by their KEGG ID. To
visualize the comparison among methods, each pathway was assigned
only one color proportional to its rank in the results from weighted
resampling, with darker red implicating lower P values. Pathways that
are identified by regular resampling or hypergeometric test but not by
the weighted resampling are notated in white. Thus, the color of the
pathway implicates its rank in the weighted resampling method, and
the discordance in the other two rows for a sample shows the different
ranking using the other two methods. Note that two samples with the
largest number of significantly enriched pathways were not presented
in this figure due to space limitations. They are the sample 16668 with
34 significant pathways and the sample 17210 with 22 significant
pathways.
doi:10.1371/journal.pone.0037595.g002
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adjusted for each gene according to the gene-specific mutation
rate, i.e., a new random number, r’i~r
1=mi
i ,i~1,:::,n, is generat-
ed, where ri[½0,1  is random numbers and mi is the gene-wise
mutation rate. Genes from G are then ordered according to r’i.
The top N genes in the ordered gene list are then assigned as
MutGenes for the resample. Note that for longer genes with large
values of mi, limmi?1r’i~limmi?1r
1=mi
i ~ri, and for shorter genes
with small values of mi, limmi?1r’i~limmi?0r
1=mi
i ~0. Therefore,
for each resample, long genes are more likely to be selected as
MutGenes, and these random sets will have the same pattern of
gene length as in the real sample. Finally, for each pathway, an
empirical P value is computed using Pemp~PrfK§kg~
#resamplesfK§kgz1
#resamplesz1
, where k is the number of MutGenes in
the observed case and K is the number of ‘‘MutGenes’’ in a
resample.
Pathway crosstalk
We proposed the node-based pathway crosstalk using the Jaccard
coefficient (JC) measurement, which has been widely applied in set-
based analysis [16,17]. Let U indicate the set of genes in pathway
A and V indicate the set of genes in pathway B, the native JC is
computed as follows: JC(A,B)~
U\V
U|V
.
To account for the presence of length bias, we also computed
JC in each weighted resample and computed an empirical
P value for each pair of pathways as follows: P(emp,JC)~
#fJC(p)§JCgz1
#resamplesz1
, where JC(p) is the JC value in the p
th
resampling.
Co-mutated pathway map
Pathways that are frequently co-mutated across multiple
samples could implicate coordinated functions at systems level.
To investigate co-mutation events, we first constructed a pathway
mutation profile across related samples. As shown in Figure 1d, for
each pathway, its mutation status is defined by a binary indicator,
i.e., a pathway is indicated as 1 if it is significantly enriched by the
weighted resampling strategy; otherwise, 0. For a pair of pathways
denoted by A and B, four categories were proposed to describe the
combination pattern of their mutation statuses, i.e., (a) both
pathway A and B are significantly enriched, and thus harbor
MutGenes, in the same sample, (b) pathway A was significantly
enriched, but pathway B was not, (c) pathway B was significantly
enriched, but pathway A was not, and (d) neither pathway A nor
Table 1. Summary of the sample information and significant pathways (PBonferroni,0.05) for the lung adenocarcinomas samples.
Sample ID # MutGenes # MutGenes in KEGG
# pathways by
weighted resampling
# pathways by regular
resampling
# pathways by
hypergeometric test
17210 49 32 22 27 28
16668 38 27 34 32 35
16660 36 22 14 20 21
16835 30 18 2 4 4
16686 29 17 4 5 5
16678 28 20 8 11 17
17759 24 12 1 1 2
17290 23 15 5 5 5
16628 22 13 3 4 5
16632 20 16 10 16 19
17218 1 7 91 12
16953 16 12 14 16 19
16608 1 3 75 77
16734 1 3 91 33
16802 13 9 7 10 10
17174 13 12 17 20 20
17262 13 9 10 10 10
17268 12 10 4 8 6
16600 11 7 12 13 12
16724 11 10 2 3 3
17060 1 1 84 86
16949 1 0 61 11
17042 1 0 64 56
17156 1 0 71 11
17242 1 0 77 78
17763 1 0 98 91 0
MutGenes: mutation genes.
doi:10.1371/journal.pone.0037595.t001
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was subsequently formulated, and Fisher’s exact test was
performed to indicate whether the mutation profiles of the two
pathways were correlated. Of note, unlike the previous studies
which typically counted all pathways that were involved [9], here
we only included the significantly enriched pathways identified by
our weighted resampling method, as the mutation events in other
pathways could be raised by chance.
Results
Case study 1: lung adenocarcinomas
Pathway enrichment test. For the 33 lung adenocarcino-
mas samples applicable for pathway enrichment test, the number
of MutGenes ranged between 10 and 49, and most (24/
33=72.72%) were no more than 20 (Figure S1). Using the
weighted resampling strategy, 26 samples were identified to have
at least one significantly enriched pathway (PBonferroni,0.05). As
shown in Figure 2, the number of significant pathways varied
greatly among samples. The largest number of significant
pathways were observed in the sample 16668, with 34 pathways
significantly enriched among 38 MutGenes (Table 1), followed by
the sample 17210, with 22 significant pathways among 49
MutGenes (data not shown in Figure 2 due to space limitation).
Three samples (samples 17174, 16953 and 16660) in the following
have 17, 14 and 14 significant pathways, each of which has 13, 16
and 36 MutGenes respectively (Figure 2). Conversely, there are
five samples that have only one significant pathways based on the
weighted resampling method, while their MutGenes range
between 10 and 30, indicating that the number of MutGenes
has less influence on the number of significantly enriched
pathways in each sample.
The most frequently mutated pathways that occurred in more
than 10 samples are hsa05220: chronic myeloid leukemia (13/26
samples), hsa05212: pancreatic cancer (12/26 samples), hsa05214:
glioma (12/26 samples), hsa05213: endometrial cancer (11/26
samples), hsa05218: melanoma (11/26 samples), and hsa05223:
non-small cell lung cancer (11/26 samples). The other lung cancer
related pathway, hsa05222: small cell lung cancer, occurred in 3
samples. Table S1 listed the MutGenes that are contributable to
the enrichment of these pathways in each of the corresponding
samples.
Comparison of pathway enrichment methods. As a
comparison, we also implemented the standard hypergeometric
test and the regular resampling strategy, both of which build on
the assumption that all genes have an equal chance of harboring
Figure 3. Pathway enrichment map for the lung adenocarcinomas samples. For each sample, the top panel shows the pathway crosstalk
map, and the bottom panel shows the genes contributing to the crosstalk. In the top panel, each node represents a pathway with the node color
proportional to the pathway enrichment P value. The edge represents crosstalk event between the connected nodes (pathways), with edge width
proportional to shared MutGenes and edge color proportional to the P value of the crosstalk event. In the bottom panel, a matrix shows the profile of
genes in the significant pathways, with rows for MutGenes and columns for pathways. When a MutGene is observed in a pathway, the corresponding
box is in red.
doi:10.1371/journal.pone.0037595.g003
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pathway were adjusted by Bonferroni multiple testing correction.
For the regular resampling method, the empirical P value for each
pathway was also adjusted by Bonferroni correction. In all three
methods, significant pathways were selected as those with
PBonferroni,0.05.
We compared the results of the different methods in two ways:
the overlapped pathways and the rank of the overlapped
pathways. As shown in Figure 2 and Figure S3, approximately
two thirds (17 out of 26) of lung adenocarcinomas samples with $1
significant pathways have more overlap pathways between the
regular resampling method and hypergeometric test than those
between regular and weighted resampling methods or those
between hypergeometric test and weighted resampling method. In
most samples, the pathways identified by the weighted resampling
strategy are less than those of regular resampling and standard
hypergeometric test (Table 1, Figure S3). Next, we examined the
rank of the results using these methods and found that the two
resampling based methods showed similar ranking for pathways,
while the ranking order of pathways gleaned from the hypergeo-
metric test differs from the other two methods. This is shown by
the inconsistency of colors in Figure 2.
Given the difference of the overlap and the rank, we observed
that the dissimilarity typically occurred at the end of the pathway
list, while the three methods differ only slightly among the most
significant pathways. This result indicates that the weighted
resampling strategy mainly affects marginally significant pathways,
while the pathways with strong evidence of enrichment signals
were robust to the gene length bias. This is consistent with a
previous work by Wendl et al. [7], who also found that most
pathways identified by the standard hypergeometric test did not
substantially depart from those identified through unbiased
methods, especially for those ranked at the top of the lists.
However, the pathways at the bottom of the enrichment lists tend
to be false positives, and could only be distinguished when
explicitly adjusting the potential biases.
The pathways that are most frequently identified by hypergeo-
metric test but not by weighted resampling include hsa04360:
axon guidance (6/26 samples) and hsa05216: thyroid cancer (5/26
samples), followed by hsa04010: MAPK signaling pathway and
hsa04012: ErbB signaling pathway in 4 samples, and all the others
in less than 4 samples. It is not surprising to see the axon guidance
pathway, because it has a large proportion of long genes, and the
median gene length of this pathway falls into the upper region of
the whole distribution (Figure S2). Similarly, the pathways that are
most frequently identified by standard resampling but not by
weighted resampling include hsa04360: axon guidance in 5
samples, hsa04010: MAPK signaling pathway in 4 samples,
hsa04012: ErbB signaling pathway in 4 samples, and others in less
than 4 samples.
Pathway crosstalk. A total of 18 samples were observed to
have at least 2 pathway crosstalk events (Pemp,0.05). We
performed multiple testing correction but found no event had
PBonferroni,0.05. Thus, we selected crosstalk events based on their
nominal P values, i.e., those with Pemp,0.05. As shown in Figure 3,
the crosstalk maps of these 18 samples fell into two major groups:
one group with intensive and strong edges among the significant
pathways (Figure 3a–3f, 3h, and 3l–3o) and another with sparsely
connected networks. Most of the samples in the former group
formed cliques or close-to-clique topological units. Here a clique
means a fully connected graph in which any two nodes are
connected by an undirected edge. In addition, the nominal P
values of these crosstalk events based on the weighted resampling,
as indicated by the darkness of the edges, are typically lower than
the later group. The pathways that are frequently involved in this
group are mainly related to cancer, such as those with their
KEGG ID starting with hsa052XX (X denotes any digit)
belonging to the ‘‘human diseasesRcancers’’ category in KEGG
Figure 4. Co-mutation pathway map for the lung adenocarcinomas samples. Node represents pathways that have been identified as
significant in at least one sample. An edge between pathways indicates a significant co-mutation event, with edge width proportional to the number
of occurring samples of the co-mutation event, and edge color representing the P values of the event. Darker edge indicates lower P values.
doi:10.1371/journal.pone.0037595.g004
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definition of pathways in the KEGG database, these cancer
pathways share a large proportion of component genes. Further
examination of the mutated genes showed that clique-based
crosstalk was typically driven by several ‘‘hot’’ MutGenes that
participate in multiple cancer-related pathways. For example, the
genes TP53 and KRAS co-occur in 11 clique-based crosstalk maps
(Figure 3a–3c, 3e, 3f, 3h, 3l–3o), as do other genes such as RB1,
PIK3CD, and PDGFRA.
Five samples formed a sparsely connected crosstalk map
(Figure 3g, 3i, 3j, 3k, and 3p). Although cancer-related pathways
are still the major functional participants in this type of map, there
are additional pathways involved, such as hsa04210: apoptosis and
hsa04620: toll-like receptor signaling pathway. Investigation of the
MutGenes in this type did not show a strong trend toward any
gene(s) substantially contributing to the crosstalk events as
observed in the clique-group. Finally, two samples displayed the
rarest crosstalk events (Figure 3q and 3r), both of which are
dominated by the genes APC and TP53.
Pathway co-mutation profile. To explore the co-mutation
events that occur among pathways, we started with a list of
significantly enriched pathways for each sample (see above). To
ensure high quality, pathways that harbored MutGenes but were
not significant in a sample were not included for this sample in the
co-mutation analysis. As a result, a total of 49 pathways and 26
samples were involved.
We selected pathways that were co-mutated in 2 or more
samples, and had a co-occurrence P value that was nominally
significant. As shown in Figure 4, two groups were self-clustered,
one of which contains several cancer-related pathways, and the
other contains several immune-related pathways. In the cancer-
related cluster, we observed hsa05214: glioma, hsa05218: mela-
noma, hsa05219: bladder cancer, hsa05220: chronic myeloid
leukemia, and hsa05212: pancreatic cancer. Interestingly, we
observed several immune-related pathways in the other cluster,
such as hsa04650: natural killer cell mediated cytotoxicity,
hsa04660: T cell receptor signaling pathway, hsa04662: B cell
receptor signaling pathway, and hsa04210: apoptosis.
Case study 2: glioblastoma
For the glioblastoma MutGenes, there were a total of 18
samples eligible for the pathway enrichment test (Figure S1), each
of which was required to have at least 5 MutGenes. Applying all
three methods, i.e., weighted resampling, regular resampling, and
the hypergeometric test, we found 15 samples were enriched with
at least one pathway by the weighted resampling methods, and
these samples were used for the subsequent analysis.
As shown in Figure 5, the similar trend of pathway overlap and
ranking order has been observed in GBM samples as in the lung
adenocarcinomas samples. The ranking order between the two
resampling methods are closer to each other, and in all the 15
GBM samples the overlapped pathways are found more frequently
in the regular resampling method and hypergeometric test than in
the weighted resampling results (Figure S4). The most frequently
enriched pathways are hsa05200: pathways in cancer (11/15
samples), followed by hsa05214: glioma (9/15 samples), hsa05218:
melanoma (9/15 samples), and so on (Figure 5).
A total of 8 samples were observed to have at least two pathway
crosstalk events (Figure 6). Similarly, most of them formed a
clique-based topological unit with intensive connections contrib-
uted by several ‘‘hot’’ MutGenes such as TP53, EGFR, RB1,
PIK3R1, and PTEN [3,18].
Co-mutated pathways in GBM samples are not as prevalent as
in lung cancer samples. As shown in Figure 7, there are only five
co-mutated events that were observed to be significant (nominal P
value,0.05, represented by the five edges in Figure 7), involving 5
pathways (represented by the five nodes in Figure 7). They are the
pathways of hsa05214: glioma, hsa05218: melanoma, hsa05215:
prostate cancer, hsa05219: bladder cancer, and hsa05222: small
cell lung cancer. The most frequent co-mutation event was
between the pathway of glioma (hsa05214) and prostate cancer
(hsa05215), and the pathway of melanoma (hsa05218) and
prostate cancer (hsa05215), both of which occurred in 7 samples.
Discussion
We proposed a bias-reducing strategy in the pathway enrich-
ment test for sample-centered cancer mutations primarily identi-
fied from NGS data. By taking the background mutation rate
individually, our method performs weighted resampling for
pathway enrichment analysis in a sample-specific fashion. Based
on this, advanced pathway analyses such as pathway crosstalk as
well as pathway co-mutation events could be examined robustly
after adjusting the sample-specific mutation rate. Note that our
analyses are computationally oriented and with no experimental
validation yet. Thus, caution should be taken in interpretation of
the results. Although these results are statistically sound, validation
in the future work, either by experiments or by other computa-
tional approaches, would affirm our findings of driver pathways.
Figure 5. Pathway enrichment test in the glioblastoma
samples. Pathways are represented as rectangles and organized by
samples. For each sample, the sample ID is presented on the left and
the three rows on the right correspond to results from the weighted
resampling method (top row), the regular resampling method (middle
row), and hypergeometric test (bottom row), respectively. For each
method, the pathways were placed from left to right according to their
P values with lower P values on the left, and, when multiple pathways
have the same P values, they were ordered by their KEGG ID. To
visualize the comparison among methods, each pathway was assigned
only one color proportional to its rank in the results from weighted
resampling, with darker red implicating lower P values. Pathways that
are identified by regular resampling or hypergeometric test but not by
the weighted resampling are notated in white. Thus, the color of the
pathway implicates its rank in the weighted resampling method, and
the discordance in the other two rows for a sample shows the different
ranking using the other two methods.
doi:10.1371/journal.pone.0037595.g005
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e37595As has been well-studied in previous research, the cancer
genome harbors both ‘‘driver’’ mutations, which contribute to the
malignancy of cancers, and ‘‘passenger’’ mutations, which have no
obvious relationship with the cancerous cells. Many of the
passenger mutations are likely by-product events rather than
causal factors of the abnormality of the cancer genome, and they
could occur randomly in the genome. Due to the limitation of our
current knowledge, it is still hard to confidently distinguish driver
mutations from passenger mutations, and almost all the current
pathway-level analyses use the two types of mutations together. In
such a context, it is necessary to adjust potential biases when
handling the data to avoid false positive discoveries.
In this study, considering the sample and disease specific
mutation characters, we used different cutoff values when selecting
lung samples and GBM samples for pathway analysis. Preferably,
a cutoff value around 10 to 20 would statistically be more
appropriate to ensure the eligibility of the test [19]. In cancer
genomes, the mutation rate and mutation patterns differ greatly
among various types of cancer, resulting in a great variety of the
number of mutation genes among cancer samples. For example,
Figure 6. Pathway enrichment map for the glioblastoma samples. For each sample, the top panel shows the pathway crosstalk map, and the
bottom panel shows the genes contributing to the crosstalk. In the top panel, each node represents a pathway with the node color proportional to
the pathway enrichment P value. The edge represents crosstalk event between the connected nodes (pathways), with edge width proportional to
shared MutGenes and edge color proportional to the P value of the crosstalk event. In the bottom panel, a matrix shows the profile of genes in the
significant pathways, with rows for MutGenes and columns for pathways. When a MutGene is observed in a pathway, the corresponding box is in red.
doi:10.1371/journal.pone.0037595.g006
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more mutation genes compared to other types of cancer [20,21].
In our work, we found a higher cutoff value such as 10 worked
reasonably for lung samples, resulting in a selection of an
appropriate number of samples for eligible pathway analysis.
However, if the same cutoff value (i.e., 10) was applied to GBM
samples, it would have only 7 samples after filtering, all of which
belong to the treated group, for follow up pathway analysis. As
shown in the original work [3], the treated group generally
contains more mutations than the untreated group. To make the
analysis informative, we subsequently decreased the cutoff value to
5 in GBM sample analysis. This adjustment ensured us to include
enough samples from the untreated group.
Our weighted resampling method depends on the gene-wise
mutation rate, which relies on two factors, the sample-specific
background mutation rate m and the particular gene length l.
Inclusion of m ensures that when comparing different individual
samples, and even different diseases, the analysis can be built on
the same scale. Thus for cross-sample analysis, such as the
pathway co-mutation map, the sample-specific rate m is particu-
larly important. However, for a given sample in which m is fixed,
the gene-wise mutation rate will mainly behave as a function of
gene length. Our weighted resampling method explicitly incorpo-
rates gene-wise mutation rate in order to build the gene-length
matched null distribution for each pathway. Thus, the empirical P
values obtained in this way can overcome the length bias and
provide more accurate statistic evaluation of the enrichment
signals.
The estimation of the background mutation rate in most studies
adopted the formula m=rNS=rS6R, where rNS is the nonsynon-
ymous (NS) mutation rate, rS is the synonymous (S) mutation rate,
and R is the ratio of NS to S substitutions [11,12,13,15]. rS can be
directly computed by rS={#synonymous}/{#sequenced base
pairs}, and R can be estimated through a random mutation model
that takes into consideration nucleotide composition in the coding
regions [22,23]. In our study, we used the somatic mutation data
for lung and GBM samples which were initially detected through
targeted sequencing in pre-selected genes. Although in each study,
hundreds of genes were sequenced, they still did not reach the
genome-wide scale and the number of NS/S mutations was
limited in each sample. The original studies for these two datasets
estimated the mutation rate by collapsing all samples [11], or by
sub-groups of samples [3], rather than computing individual level
mutation rate. In future studies, since mutation data from whole
genome sequencing and whole exome sequencing will be easily
obtained for individuals [24], our method will find more
applications by using these data for mutation background
estimation.
As shown in the lung cancer sample, there were indeed several
pathways with long genes filtered out by the weighted resampling
strategy, while they were included in both regular resampling and
the hypergeometric test. However, the difference among the three
methods we tested seems to only affect marginally significant
pathways, i.e., pathways that are ranked at the end of the resultant
pathway list by each method (Figure 2). This is not surprising, as
the length bias may not be substantially significant in all samples,
and the sequenced genes we used in this study are limited to pre-
defined candidate genes rather than genome-wide sequencing. For
example, the lung cancer data was collected from a total of 623
candidate genes consisting of oncogenes, tumor suppressor genes,
genes from protein kinase families, and others [11], and the
glioblastoma data was from sequencing of 601 pre-selected genes
[3]. Nevertheless, in both cases, there are pathways that were
identified as significant through standard statistical tests (e.g.,
hypergeometric test or the regular resampling method) but were
found to be non-significant by the weighted resampling strategy
after considering gene length bias. Importantly, most of these
error-prone pathways contain long MutGenes. An example is the
pathway of axon guidance (hsa04360) in 6 lung cancer samples.
The rejection of these long gene pathways by the weighted
resampling method shows the rationality of reducing length bias.
It is important to recognize the long gene effect, and the
possibility of false discovery using methods without length bias
adjustment. For example, Gu et al. [9] analyzed the co-mutation
profile of pathways in the same lung adenocarcinomas data as we
used here. However, without appropriate adjustment of gene
length, several pathways that are known to harbor long genes were
included in their co-mutated pathway network, such as axon
guidance, long-term potentiation, and long-term depression [9].
These pathways function in neuro- and brain-systems, but there is
rare evidence showing their functions related to cancer. We
provided an updated co-mutation profile using the significant
pathways resulting from the weighted resampling strategy,
effectively removing these possible false discoveries.
The gene length problem not only exists in mutation data, but
many other types of data where there is a necessary step to map an
original analysis unit (e.g., mutated locus, SNP, CNV, methylation
locus) to the unit of gene (i.e., the unit for pathway organization).
For example, in pathway enrichment analyses of genome-wide
association studies, in which millions of single nucleotide
polymorphisms (SNPs) are genotyped using microarray chips,
the step of mapping SNPs to genes could generate more SNPs for
Figure 7. Co-mutation pathway map for the glioblastoma
samples. Node represents pathways that have been identified as
significant in at least one sample. An edge between pathways indicates
a significant co-mutation event, with edge width proportional to the
number of occurring samples of the co-mutation event, and edge color
representing the P values of the event. Darker edge indicates lower P
values.
doi:10.1371/journal.pone.0037595.g007
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PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e37595long genes and, thus, long genes would have a higher probability
to be significant. Another example is CNV data, where there is a
similar problem in that long genes tend to be more frequently
affected by CNV regions [25] and require careful adjustment
before any conclusion is made. Thus, the weighted resampling
strategy we proposed in this study for cancer mutation data could
be easily extended to other types of genetic mutations and widely
applied to different kinds of diseases.
In summary, we proposed a weighted resampling strategy to
adjust gene length bias in pathway enrichment analysis of a set of
cancer genes. This strategy incorporates gene mutation rates and is
implemented in a sample-specific way, thus enabling the
identification of a personalized pathway enrichment map.
Demonstrated in two cancer projects, the weighted resampling
strategy could effectively reduce the burden of long gene pathways
and provide a complementary method in the field.
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Figure S1 Distribution of the number of mutation genes
in the lung adenocarcinomas dataset (a) and in the
glioblastoma dataset (b). The horizontal dash lines indicate
the cutoff values we applied to select samples with appropriate
number of mutation genes for pathway analysis. The vertical dash
lines indicate that the samples on the right of the lines were
selected.
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Figure S2 Distribution of the gene length for KEGG
pathways. We used the median values of the gene lengths for
each pathway. The red line indicates the pathway hsa04360: axon
guidance.
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Figure S3 Venn diagrams showing the overlap path-
ways identified in each lung adenocarcinomas sample
by three methods: hypergeometric test (hyper), regular
resampling (regular), and weighted resampling (weight-
ed).
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Figure S4 Venn diagrams showing the overlap path-
ways identified in each glioblastoma sample by three
methods: hypergeometric test (hyper), regular resam-
pling (regular), and weighted resampling (weighted).
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